Posted by AGORACOM-JC
at 7:37 AM on Wednesday, December 9th, 2020
Commercial launch to impact first half 2021 revenue
$30 million forecasted annual peak sales
8 years of proven in-market safety Internationally
Low molecular weight heparin increasingly used to prevent COVID-19 driven complications
MONTREAL , Dec. 9, 2020 – Valeo Pharma Inc . (CSE:VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today that Health Canada has issued a Notice of Compliance for Redesca and Redesca HP low molecular weight heparin (“LMWH”) biosimilars.
“The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly being adopted across the country and is expected to help provide significant savings to provincial healthcare plans”, said Steve Saviuk , President and CEO. “With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives”.
“The Canadian LMWH market is in excess of $200 Million annually and our complete product line and differentiating clinical package will be a beneficial factor helping to rapidly secure market share in provinces across Canada ,” added Mr. Saviuk.
In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWH are also now increasingly used as a first line of defense tool in the fight against Covid-19. The World Health Organization’s (“WHO”) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.
Digital Investor Awareness Program
The Company also announces that it has launched a 12-month digital investor awareness program through AGORACOM, a multifaceted digital platform operated by AGORA Internet Services Corp. (“AGORA”), in order to enhance information availability for current and future stakeholders. The Company has agreed to remunerate AGORA $75,000 plus taxes for the above mentioned services. A first service payment of $15,000 was made on December 7, 2020 with the remaining balance split equally and due on each of February 27, 2021 , May 27, 2021 , August 27, 2021 , and December 31, 2021
Payment will be made through the issuance of the Company’s common shares with the number of common shares to be issued determined by using the closing price on each date above. Common shares issued to AGORA under this agreement will be subject to a 4-month hold period.
About Redesca
Redesca is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca has more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in Europe alone.
About Valeo Pharma
Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec , Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Posted by AGORACOM-JC
at 7:33 AM on Wednesday, December 9th, 2020
–Safe Space Technology™–
TORONTO , Dec. 9, 2020 – Kontrol Energy Corp. ( CSE: KNR ) ( OTCQB: KNRLF ) ( FSE: 1K8 ) (” Kontrol ” or ” Company “) is pleased to announce that it will be hosting a webinar presentation for investors, analysts and media for its Covid-19 detection technology (“BioCloud analyzer” or “BioCloud”). The purpose of the presentation is to provide an operating demonstration and take questions from the audience.
“Following the filing of our patent applications we are excited to demonstrate how the BioCloud technology operates and share that with the public,” says Paul Ghezzi , CEO Kontrol. “We will be providing a demonstration of BioCloud and access to the inner workings of the technology.”
As previously announced on November 30, 2020 , Kontrol has filed the following four patent applications for its BioCloud technology and the Company is pleased to provide the patent references:
UNITED STATES : Application No. 17/105,793 SYSTEM AND METHOD FOR DETECTING AIRBORNE PATHOGENS
UNITED STATES : Application No. 17/105,813 SYSTEM AND METHOD FOR OPTICAL DETECTION OF PATHOGENS
UNITED STATES : Application No. 17/105,804 COLLECTION CHAMBER FOR AN AIR SAMPLING SYSTEM
CANADA SYSTEM AND METHOD FOR DETECTING AIRBORNE PATHOGENS
Title:
Kontrol to Host BioCloud Technology Presentation for Investors, Analysts and Media
Event Date:
Thursday, December 17, 2020 – 4:30 PM Eastern Time
Presentation Type:
Audio with Presenter Controlled Slides and Teleconference
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.
Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com
BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.
About Kontrol Energy
Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
Posted by AGORACOM-JC
at 6:10 PM on Tuesday, December 8th, 2020
Understanding the world of Photonics isn’t the easiest thing small cap investors have had to understand. In fact, it may be the very hardest thing they’ve ever had to understand. However, given the fact we are the very reason current photonics devices aren’t living up to snuff trying to keep up with our surfing, streaming, binging and zooming – you start to see why understanding photonics and POET Technologies could open up investors to a whole new world.
We went beyond the press release with POET management to discuss the launch of their LightBar solution for data centers. They did a great job explaining it in terms that are both compelling yet understandable.
Before watching this video, here is some important background information.
Photonics are critical to the next phase of semiconductor development. Semiconductors are an essential component of every electronic device on the planet.
Photonic devices create, detect and manipulate light. Laser generated light is fundamental to sensing, computing, data and telecommunications, which require the fastest transfer of data possible
For example – the biggest trends in computing today:
Cloud Computing
Artificial Intelligence
5G and Edge
HERE IS THE PROBLEM
Making photonics devices that are reliable is expensive in terms of both capital and labor.
Cost declines have not kept up with Moore’s Law, with most photonics devices built one at a time – and multiple different components must be able to interconnect seamlessly without constant testing.
The Result? Integration of components at wafer-scale has not been fully implemented even by the largest companies working for the past 20 years ….. UNTIL NOW
POET has developed a unique, disruptive and differentiating new entry into photonics markets.
The POET Optical Interposer™ Platform – patented photonics integration platform that enables lower cost and higher performance across a wide range of applications
Today’s press release announcing a line of high-performance remote laser light source products for applications in Cloud-Based Data Centers might very well take POET to a whole new level,
Watch this great first interview of many with
Suresh Venkatesan, Chairman and CEO
Vivek Rajgarhia, President & General Manager
Thomas Mika, Executive Vice President and Chief Financial Officer
Posted by AGORACOM
at 9:37 AM on Tuesday, December 8th, 2020
SPONSOR: Harborside is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments, Retail Dispensaries, Cultivation and Processing and Wholesale Sales (including branded product sales). Harborside operates the only drive through dispensary in California
SAN DIEGO — On Friday the United States House of Representatives passed a bill decriminalizing marijuana at the federal level. Although it is unlikely to pass the Senate, it has industry leaders here in California excited that the conversation towards decriminalization is rolling in Washington.
After receiving some rare bi-partisan support, the Marijuana Opportunity Reinvestment and Expungement or MORE Act passed the House of Representatives by a large margin. Highlights of the bill include:
Decriminalizing marijuana federally
Establishing a 5% federal tax on all cannabis products
Prohibiting the denial of federal benefits to people convicted of cannabis-related crimes
The bill would start the process of expunging the records of those convicted of Cannabis-related offensives
Will Senn is the founder of Urbn Leaf, a marijuana dispensary in San Diego. He says that the bill has been a long time coming and that it was a historic win for the industry. He went on to say that attitudes towards marijuana are shifting around the country. “I think the writing is on the wall, right? Everybody is voting for cannabis legislation nationwide. You had five more states pass some legislation in the last election year. There’s a number of upcoming bills in the near future here.”
Marijuana has been decriminalized in California since 1996 but attitudes about the plant differ drastically around the country. According to the FBI and the Pew Research Center, in 2018 40% of the 1.65 million drug arrests from around the country were marijuana-related and 92% of them were for possession.
Jason Ortiz from the Minority Cannabis Business Association said, “So, I mean, there are thousands at the very minimum, especially on the federal level. But as you start to extend the impact statewide, it could be upwards of millions of records that would get affected.”
Ortiz added that the potential expungement of cannabis-related crimes off a person’s record could change the lives of thousands of people, “And having that on your record denies you access to housing, to jobs, to other sorts of social services.”
Although the bill passed in the House, it’s unlikely that it will see a vote in the Senate. Still, business owners like Senn see it as an important benchmark of just how far the conversation around decriminalizing marijuana has come since he entered the industry.
Posted by AGORACOM-JC
at 7:24 AM on Tuesday, December 8th, 2020
Initial sales, distribution agreements, filed patents and Government funding move BioCloud into the market
Set to ship its COVID-19 technology (“Kontrol BioCloud” or “BioCloud”) BioCloud, to customers and distributors around the world.
BioCloud is a real-time analyzer designed to detect airborne viruses, including SARS-COV-2, by continuously sampling air quality and triggering a silent, cloud-based alert to facility managers.
TORONTO , Dec. 8, 2020 – Kontrol Energy Corporation (“Kontrol” or the “Company”), a Canadian public Company (CSE: KNR) (OTCQB: KNRLF), is set to ship its COVID-19 technology (“Kontrol BioCloud” or “BioCloud”) BioCloud, to customers and distributors around the world. BioCloud is a real-time analyzer designed to detect airborne viruses, including SARS-COV-2, by continuously sampling air quality and triggering a silent, cloud-based alert to facility managers.
Initial contracts include sales with Kontrol customers and non-exclusive distribution and an exclusive distribution agreement for North America , Australia and New Zealand with United Safety and Survivability Corp.
Patents Filed On November 30th, 2020 the Company announced the filing of 4 patents for the BioCloud technology with 3 patents filed in the USA and 1 patent in Canada .
“The focus of our BioCloud technology is to help create safer spaces globally as we collectively continue to face the challenge of the COVID-19 pandemic,” says Paul Ghezzi , CEO Kontrol. “Initial deliveries are set to arrive to Kontrol customers and distributors in January 2021 . Our team has been working around the clock to launch BioCloud into the global market.”
Manufacturing With COVID-19 cases spiking globally and with increases anticipated into the winter season, BioCloud distribution plans are in high gear.
“We have the required local manufacturing capability to meet anticipated production volumes,” says Gary Saunders , VP of Kontrol. “We are pleased that the majority of our supply chain is Canadian.”
Kontrol has engaged OES Inc. a local design and contract manufacturer in London, Ontario to produce the BioCloud units. OES Inc. has a long and established history of assisting with the design and manufacturing of complex technology.
“Having BioCloud developed and now being produced in Ontario, Canada is very important to us,” continues Paul Ghezzi . “Our plans to have the initial production and supply chain sourced in Canada means that we are creating jobs while helping to solve the global pandemic that is COVID-19.”
“OES has the ability and capacity to ramp up to meet the required BioCloud manufacturing requirements and we can also scale with BioCloud as required,” says Jeff Stewart , President OES Inc. “We are committed to supporting local jobs, growth and Ontario exports.”
Kontrol receives additional federal funding On December 3rd, 2020 the Company announced that it had received advisory services and additional $500,000 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) .
“This is another important accomplishment and milestone for Kontrol and represents the continuing advancement of the BioCloud technology,” continues Paul Ghezzi . “We are grateful for and proud of this support from our federal government.”
Kontrol’s distribution agreement with United Safety and Survivability Corp Under the terms of the agreement, the exclusivity applies to the industries defined as buses, rail and locomotive, subways, ambulances, fire trucks, first responder and military vehicles, with applicable associated facilities in the geography of North America , Australia , and New Zealand . The exclusivity period is 12 months with a six month mutual renewal option and is based on 5,000 units of BioCloud per annum, on a best efforts basis, to retain exclusivity. Pricing will not be disclosed for industry competitive purposes.
Joseph Mirabile , CEO of United Safety stated, “United Safety and Survivability Corporation is committed to delivering the most innovative and reliable solutions that our customers trust to protect life and property. We are very excited to be sharing the Kontrol BioCloud technology with all of our customers. We see interest and demand for this innovative technology, which can help create safer spaces and help our customers solve many of the challenges they are facing in relation to the impact COVID-19 has on their business.”
Ongoing Service The patented and proprietary detection chamber is at the heart of BioCloud. The detection chamber is a consumable that needs to be replaced when it comes into contact with the SARS- CoV-2 virus. Kontrol is launching a new service to assist customers with the disposal and recycling of BioCloud’s propriety detection chamber.
The service allows for customers to return and recycle the detection chamber and receive a discount on future purchases of consumable detection chambers.
“This new service is a win-win as Kontrol is able to recycle various materials and customers are able to receive a discount on future purchases of the BioCloud consumables,” continues Gary Saunders .
Purchase The Company estimates a $12,000 USD per unit sale price for BioCloud based on current supply chain components. However, the Company offers volume discounts for aggregate purchases and further, the Company will offer a financing plan should customers require it.
About Kontrol BioCloud BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.
Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com
BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.
About Kontrol Energy Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
Posted by AGORACOM-JC
at 4:08 PM on Thursday, December 3rd, 2020
Announced that it was invited by one of the leading IR agencies in the U.S., Lytham Partners, to participate in its End of Year 1×1 Conference (the “Conference”) from December 7-11, 2020.
CEO Iris Bincovich will be participating on behalf of Innocan and will showcase the Company in one-on-one meetings at the Conference.
Herzliya, Israel and Calgary, Alberta–(December 3, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that it was invited by one of the leading IR agencies in the U.S., Lytham Partners, to participate in its End of Year 1×1 Conference (the “Conference”) from December 7-11, 2020. CEO Iris Bincovich will be participating on behalf of Innocan and will showcase the Company in one-on-one meetings at the Conference.
CEO Iris Bincovich states: “We are glad that Innocan was selected by Lytham Partners to participate in this important conference. This invitation outlines that we are on a promising path within our field of scientific work in combining CBD with liposomes and exosomes, to target serious diseases like Epilepsy, Alzheimer or Covid-19.”
About Innocan
The Company is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD“). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. The Company plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
For further information, please contact:
For Innocan Pharma Corporation: Iris Bincovich, CEO +972-54-3012842 [email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Posted by AGORACOM
at 1:03 PM on Thursday, December 3rd, 2020
SPONSOR: Harborside is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments, Retail Dispensaries, Cultivation and Processing and Wholesale Sales (including branded product sales). Harborside operates the only drive through dispensary in California
This week the U.S. House of Representatives is expected to vote on a bill that would remove marijuana from the Controlled Substances Act and require federal courts to expunge many prior marijuana offenses. It will be the first time the full House will vote on ending the federal prohibition of cannabis.
Morgan Fox with the National Cannabis Industry Association says House passage would “send a really strong message to not only the rest of Congress, but to a lot of other states that the time to end prohibition has come.”
The Marijuana Opportunity Reinvestment and Expungement Act (MORE Act), introduced by Rep. Jerry Nadler (D., N.Y.), would eliminate conflict between state and federal law and allow states to set their own marijuana policies.
“We don’t need to have one size fits all. We just need to get rid of prohibition and then let the states do what the states are doing. It’s essentially what the states have done already. They haven’t waited for the federal government, which is why we have a lot of these discrepancies and challenges,” said Rep. Earl Blumenauer (D., Ore.), who has long pushed for marijuana legalization.
Blumenauer and Rep. Barbara Lee (D., Calif.) — who also wrote parts of the legislation — told Yahoo Finance the bill is a racial justice issue.
“It’s coming at a time when Americans are recognizing how hopelessly flawed the criminal justice system is,” said Blumenauer.
‘You’ve got to repair the damage’
The MORE Act would impose a 5% sales tax on marijuana and marijuana products. The revenue would go toward a new trust fund for grant programs designed to help people “adversely impacted by the War on Drugs” access job training, re-entry services, legal aid, treatment and more. The bill would also provide protections prohibiting denial of federal benefits based on use, possession or conviction for a marijuana offense.
“Regardless of who you are, if you’ve been incarcerated and if you’ve done your time and you get out, you should be provided for a second chance,” Lee told Yahoo Finance. “When you’ve been incarcerated or when you have have a record based on unjust laws — they’re really targeted in many ways, Black and Brown people — then you’ve got to make restitution, you’ve got to repair the damage. This fund is about the time that was lost because of barriers to employment, because of incarceration.”
The MORE Act would open up more opportunities for marijuana businesses, including access to Small Business Administration funding. It would also require the Bureau of Labor Statistics to gather demographic data on cannabis business owners and employees to ensure people of color and economically disadvantaged people are taking part in the industry.
“That really sets out a process for equity in the industry. This is a job-creating industry, and it also provides economic opportunities for minority-owned business owners,” said Lee.Graphic by David Foster/Yahoo Finance
The House Judiciary Committee passed the MORE Act last year 24 to 10 — Rep. Matt Gaetz (R., Fla.) and Rep. Tom McClintock (R., Calif.) were the only Republicans who voted for the bill.
In an interview with Yahoo Finance, McClintock said while he didn’t endorse marijuana, it’s clear U.S. marijuana laws have “not accomplished their goals.”
“These laws have done far more harm than good. They’ve created a violent underground economy and ruined the lives of so many young people who’ve had a youthful marijuana conviction, follow them and ruin their lives,” said McClintock.
The House was scheduled to vote on the bill in September, but Democratic leadership postponed the vote because some members in tight races worried passing the MORE Act before a stimulus package could hurt them at the polls.
Nearly a month after the election, there is still no additional coronavirus relief and many Republicans are again slamming Democrats for what they see as prioritizing the cannabis bill over coronavirus relief efforts.
Democrats have already passed two versions of the Heroes Act and argue it’s the Trump administration and Republican Senate that’s holding up stimulus talks.
Posted by AGORACOM-JC
at 7:21 AM on Thursday, December 3rd, 2020
Announced that the Company is in receipt of advisory services and up to $500,000 in research and development funding from National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to complete final commercialization and mass production requirements for its Covid-19 technology, the Kontrol BioCloudTM analyzer
Company has commenced initial production of BioCloud units for delivery in approximately 5 to 6 weeks. Initial deliveries include the sale of units to distributors and Kontrol customers.
Further, the Company will deliver demonstration units to pilot customers in the Middle East.
TORONTO, ON / December 3, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that the Company is in receipt of advisory services and up to $500,000 in research and development funding from National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to complete final commercialization and mass production requirements for its Covid-19 technology, the Kontrol BioCloudTM analyzer (“BioCloud analyzer” or “BioCloud“).
“This is another important accomplishment and milestone for Kontrol and represents the continuing advancement of the BioCloud technology,” says Paul Ghezzi, CEO Kontrol. “The focus of our BioCloud technology is to help create safe spaces for all as we collectively continue to face the challenge of the COVID-19 pandemic. We are thankful for this support from NRC IRAP.”
Production
The Company has commenced initial production of BioCloud units for delivery in approximately 5 to 6 weeks. Initial deliveries include the sale of units to distributors and Kontrol customers. Further, the Company will deliver demonstration units to pilot customers in the Middle East. The Company will announce those sales which are material and other sales will be reported in the applicable quarterly financial statements as ordinary course.
About Kontrol BioCloudTM
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.
Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com
BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.
About Kontrol Energy
Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com
Posted by AGORACOM-JC
at 7:30 AM on Wednesday, December 2nd, 2020
The following is a summary of key balance sheet items as of September 30, 2020, as compared to figures as at December 31, 2019:
Cash and cash equivalents were C$2,393,060 as compared to C$2,569,602;
Current assets of C$3.6 million as compared to C$3.2 million;
Total assets of C$3.7 million as compared to C$3.3 million; and
Current liabilities of C$3.07 million as compared to C$1.4 million.
Herzliya, Israel and Calgary, Alberta–(December 2, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today its financial and business results for the three and nine months period ended September 30, 2020 (the “Financial Statements“) and provide highlights and comments on these results. This news release should be read in conjunction with the Financial Statements and corresponding Management’s Discussion and Analysis available on the Company’s profile at www.sedar.com. The Company’s Financial Statements have been prepared in accordance with International Financial Reporting Standards (“IFRS“).
“This has been a milestone quarter for Innocan. After successfully completing our $5.1M financing, we have laid the groundwork for full commercialization of our CBD based products. We are completing the manufacturing process in Europe and the USA and have received regulatory approvals for marketing in Europe and the USA” stated Iris Bincovich, Chief Executive Officer of Innocan.”
Business highlights for the three months period ended September 30, 2020
On June 5, 2020, the Company announced the commencement of commercial production of its Derma CBD line in Portugal. The first product currently being manufactured is the patent pending Relief & Go Pain Relief spray.
On June 26, 2020, the Company announced the results from the first dermal clinical study of the Relief & Go and SHIR product lines. The double-blind, randomized control study assessed the tolerance degree of the Company’s CBD topical products and demonstrated the products to be non-irritating to the skin.
On July 9, 2020, the Company announced its collaboration with Recipharm, Israel (“Recipharm“) to synthesize and analyze cannabinoid loaded exosomes. Recipharm unites more than 30 facilities across 10 countries offering a range of services with a focus on two areas of operation: pharmaceutical development services and manufacturing services.
On July 13, 2020, the Company announced that it received notice from the U.S. Food and Drug Administration that Innocan’s over-the-counter Relief & Go Pain Relief spray received technical validation and approval to commence marketing in the USA. Innocan’s pain relief formulation contains a combination of magnesium oil, methyl salicylate, menthol and CBD. The Relief & Go Pain Relief spray is designed to target and relieve pain related to muscles and joints. The unique formulation is administered with a simple dose by spray, roll-on or lotion.
On August 6, 2020, the Company announced that its SHIR CBD Derma Cosmetic product line successfully passed safety assessments in accordance with European Union (EU) cosmetic regulation No. 1223/2009 and received an EU Cosmetic Product Safety Report for marketing in the European Union.
On August 11, 2020, the Company announced it entered into a manufacturing and distribution agreement (the “ESI Agreement“) with Endless Sky Incorporated (“ESI“), a large-scale Canadian cannabis extractor based in Calgary, Alberta. Under the ESI Agreement, ESI will serve as the exclusive distributor of Innocan’s CBD products in Canada under a license granted by Innocan. ESI will manufacture Innocan’s CBD products at ESI’s Health Canada licensed facility in Redvers, Saskatchewan. ESI’s manufacturing and distribution rights consist of the Relief & Go Pain Relief spray and cream and the SHIR Eye Serum, Face Cream and Night Cream. The ESI Agreement is conditional upon ESI receiving Health Canada approval no later than December 31, 2020. According to the ESI agreement, ESI shall pay Innocan a cash license fee per product as well as royalties based on net sales of the products distributed by ESI. The ESI Agreement is for a term of 12 months and will be automatically extended for additional periods of 12 months, each based on ESI achieving minimum sales targets for the previous 12-month period.
On August 19, 2020, the Company entered into a manufacture and supply agreement with GNB Swiss Investments SA to manufacture and supply GNB Swiss Investments SA products based on Innocan’s formulas, which will be distributed by GNB Swiss Investments SA under its own brand.
On August 20, 2020, the Company announced that Innocan entered into a distribution agreement (the “Cloud 9 Agreement“) with Cloud 9 Switzerland LLC (“Cloud 9“) to sell the Company’s SHIR Beauty and Relief & Go product lines in Italy and Switzerland. Under the terms of the Cloud 9 Agreement, Cloud 9 will distribute Innocan’s unique cosmetic CBD products in Italy and Switzerland on a nonexclusive basis. The Cloud 9 Agreement defines the ordering and delivery mechanisms for the products and the marketing cooperation between the parties. The parties intend to carry out the Cloud 9 Agreement immediately, following the completion of all registration and regulatory requirements in Italy and Switzerland.
On September 15, 2020, the Company announced it completed a cosmetic clinical study examining the impact of its SHIR Premium CBD Facial Serum, containing 300 mg of cannabidiol, on skin hydration.
Financial highlights for the three months period ended September 30, 2020, compared to the three months period ended September 30, 2019:
The following are financial highlights of Innocan’s operating results for the three months period ended September 30, 2020, compared to the three months period ended September 30, 2019:
Research and development expenses amounted to C$654,000 for the three months period ended September 30, 2020 compared to C$149,000 for the three months period ended September 30, 2019. The increase is primarily attributable to an increase in research expenses due to the new research agreements entered into during the nine months period ended September 30, 2020 with Yissum Research Development Company and Ramot at Tel Aviv University, along with an increase in patent application expenses.
Selling, general and administrative expenses amounted to C$902,000 for the three months period ended September 30, 2020 compared to C$1,858,000 for the three months period ended September 30, 2019. The decrease in selling, general and administrative expenses is primarily attributable to the reduction of issuance expenses.
The following is a summary of key balance sheet items as of September 30, 2020, as compared to figures as at December 31, 2019:
Cash and cash equivalents were C$2,393,060 as compared to C$2,569,602;
Current assets of C$3.6 million as compared to C$3.2 million;
Total assets of C$3.7 million as compared to C$3.3 million; and
Current liabilities of C$3.07 million as compared to C$1.4 million.
About Innocan
The Company is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
Innocan signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique controlled release liposome to be administrated by injection. Innocan plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research at the Hebrew University, to test the liposome platform on several potential indications. Innocan is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Posted by AGORACOM-JC
at 7:25 AM on Tuesday, December 1st, 2020
ImagineAR™ Elves Help Interactive 3D Santa Come into Homes Easily
Using the free ImagineAR™ app on their phones, parents can bring a life-sized talking 3D Santa directly from the North Pole into their living rooms for photos and videos.
NORTH POLE, Dec. 1, 2020 – ImagineAR Inc. (CSE: IP) (OTC: IPNFF) Santa Claus knows how important it is to keep children and families safe and healthy, so for the first time ever, he will enter homes of good little boys and girls via their parents’ smartphones, rather than chimneys. Using the free ImagineAR™ app on their phones, parents can bring a life-sized talking 3D Santa directly from the North Pole into their living rooms for photos and videos.
“Yes, it’s true,” said Santa. “The elves at ImagineAR and I wanted to bring some early holiday cheer to children this year, since social distancing has stopped my visits to shopping malls, stores and special events. We wanted to make sure children could still have their yearly photo with me and could even dance with me in their very own homes,” the jolly one said.
Inspired by the distraught 5-year old daughter of a fellow elf, ImagineAR head elf Alen Paul Silverrstieen and his team got to work. “This little girl wanted to visit Santa before the holidays and while she understood it wasn’t safe, it broke Santa’s heart,” said Silverrstieen. “The big guy was quite clear- make it so parents, grandparents and friends can use their smartphone to bring him directly into the homes of children everywhere for photos. We went a step further with Santa’s magic- using the free ImagineAR app and from the phone, folks can even record video of Santa Claus dancing with their little ones in front of their very own trees to share with family and friends!” he announced proudly.
To have Santa drop in to your home, just download the free ImagineAR app in the IOS App Store or Google Play on your mobile device, select “AR Near Me”, select your preferred Santa experience from the bottom of the screen, and Santa will magically appear right in front of you through your phone. The ImagineAR app has multiple Santa experiences to choose from. “In case a half-eaten cookie and empty glass of milk aren’t enough, we can even provide parents with photographic ‘proof’ that Santa was in their home on Christmas Eve stealthily with his big bag of toys,” whispered Silverrstieen.
“I’m an old guy, set in my ways,” chuckled Santa. “Don’t tell anyone, but I’ll likely still use chimneys, too. But my ImagineAR elves have really outdone themselves..Wishing everyone a very merry Christmas! Ho! Ho! Ho!”
About ImagineAR ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.
For more information or to explore working with ImagineAR, please visit www.imagineAR.com .
We encourage you to do your own due diligence and ask your broker if ImagineAR Inc. (cse: IP) is suitable for your particular investment portfolio*.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward-looking information is based on certain key expectations and assumptions made by ImagineAR’s management. Although ImagineAR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because ImagineAR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
